-The Hindu   Low Muslim representation appears to be a striking feature of this year's admissions to nursery classes in Delhi's private schools. Of 92 schools which provided some sort of information on their websites, as many as 20 (or their branches) admitted no Muslim child while 17 admitted only one Muslim child each. While the sketchy nature of available data – with only a few schools willing to reveal the numbers of...

Today is 20th March and it was this day in 2009 when the new form of Right to Information Act (RTI Act) was enacted in J&K by Omar Abdullah led Government soon after coming to power. Prior to 2009 we had an RTI law passed by PDP Congress coalition Government headed by Mufti Mohammad Syeed in 2004 (J&K RTI Act 2004). The 2004 version of RTI Act was much weaker...

-The Economic Times The Delhi High Court on Friday quashed criminal proceedings against Microsoft India, a fortnight after the company was exempted by a trial court in a similar case for hosting objectionable content online.  Microsoft India is the only company, out of the 21 websites, against whom both criminal and civil proceedings pending in the capital's High Court and trial court now stand quashed.  Justice Suresh Kait set aside the trial court's...

National AIDS Control Programme urged to move beyond medicine-centric approach The government programmes for children suffering from HIV/AIDS should move from medicine-centric approach to include nutrition and preventive care, the National Commission for Protection of Child Rights (NCPCR) has recommended. In its recently released report ‘Rights and entitlements of children affected and infected by HIV/AIDS 2010-11’, the organisation also advocated provisions for issuing BPL cards to children who have lost their...

In a landmark decision, India’s intellectual property office on Monday allowed Hyderabad-based Natco Pharma Ltd to make and sell a copycat version of German drug maker Bayer AG’s patented cancer treatment Nexavar. It’s the first time that an Indian company has been granted the so-called compulsory licence to market a generic version of a patented drug. The drug, patented by Bayer in India in 2008, is used in the treatment of...